Article

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas

2023-06-07

Abstract excerpt

Despite overall good prognosis associated to thyroid cancer (TC), poorly differentiated carcinomas (PDTC) and anaplastic carcinomas (ATC, one of the most lethal human malignancies) represent major clinical challenges. We have shown that the presence of active T172-phosphorylated CDK4 predicts sensitivity to CDK4/6 inhibitory drugs (CDK4/6i) including palbociclib. Here, CDK4 phosphorylation was detected in all well...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 44b14cc6-7c50-5cc3-8d09-4cff8aa0c63b
DOI: 10.1101/2023.06.05.543656

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomasDOI 10.1101/2023.06.05.543656Read

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomasSemantic proximity Read

Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome ProfilingSemantic proximity Read

Mechanistic Insights of Thyroid Cancer Progression.Semantic proximity Read

The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.Semantic proximity Read

Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Semantic proximity Read

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclibSemantic proximity Read

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibitionSemantic proximity Read

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read

Evaluating new treatments for anaplastic thyroid cancer.Semantic proximity Read

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.Semantic proximity Read

Novel targeted therapies and immunotherapy for advanced thyroid cancers.Semantic proximity Read

Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.Semantic proximity Read